Rizwan Alimohammad, MD
Cardiovascular Disease · Albany, NYNPI 1750546008
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Boston Scientific at 31.4% of the total. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,386 payments — averaging $252.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$110K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$105K
- Cvrx, Inc.$52K
- Medical Device Business Services, Inc.$44K
- Atricure, Inc.$12K
- Medtronic$11K
- plus $15K from 30 others
Across 95 payments — averaging $2886.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$177K
- Cvrx, Inc.$87K
- Medtronic$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
What the payments were for
- Consulting fees$110,20632%
- Speaking & faculty fees$197,60057%
- Travel & lodging$12,9994%
- Food & beverage$28,4578%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 459 | $109,563 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 210 | $105,188 |
| Cvrx, Inc. | 94 | $52,227 |
| Medical Device Business Services, Inc. | 27 | $44,300 |
| Atricure, Inc. | 22 | $11,645 |
| Medtronic(2 entities) | 66 | $10,941 |
| Biosense Webster, Inc. | 62 | $8,300 |
| Edwards Lifesciences | 106 | $2,652 |
| Novartis | 169 | $1,375 |
| Pfizer | 38 | $476 |
| Abbott | 25 | $415 |
| Johnson & Johnson | 20 | $370 |
| Amgen | 20 | $339 |
| AstraZeneca | 14 | $219 |
| AOP Health US, LLC | 1 | $196 |
| Boehringer Ingelheim | 10 | $174 |
| E.r. Squibb & Sons, L.L.C. | 13 | $169 |
| Abiomed | 4 | $120 |
| Biotronik Inc. | 1 | $98 |
| Gilead | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Itamar Medical Inc | 1 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Merck | 2 | $34 |
| Sanofi | 1 | $33 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| GSK | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Altathera Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$100,985
- Carto 3$51,473
- Barostim Neo System$50,692
- EMBLEM MRI S-ICD$22,200
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$11,088
- GENERAL BRADY$8,175
- GENERAL - THERAPIES$7,913
- Reveal LINQ$3,762
- Farapulse$3,209
- LUX-Dx Insertable Cardiac Monitor$2,752
- Arctic Front$2,388
- GENERAL PAIN MANAGEMENT$846
- Rapiblyk$391
- ATRICURE ATRICLIP LAA EXCLUSION$348
- EPI-SENSE GUIDED COAGULATION SYS$348
- VIGILANT$241
- SYNERGY ABLATION SYSTEM$153
- LUX-DX$126
- Rhythmia Mapping System$114
How this compares
$349,276 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 680 | $894,810 |
| EntrestoSacubitril/Valsartan | 163 | $241,071 |
| XareltoRivaroxaban | 91 | $114,974 |
| FarxigaDapagliflozin Propanediol | 46 | $54,369 |
| Dofetilide | 121 | $47,480 |
| JardianceEmpagliflozin | 31 | $34,522 |
| Repatha SureclickEvolocumab | 24 | $33,687 |
| MounjaroTirzepatide | 17 | $17,457 |
| Nadolol | 114 | $13,463 |
| OzempicSemaglutide | 13 | $12,284 |
| Metoprolol Succinate | 536 | $8,320 |
| Amiodarone Hcl | 170 | $7,645 |
| Atorvastatin Calcium | 562 | $6,217 |
| Bumetanide | 89 | $3,365 |
| Ranolazine ErRanolazine | 16 | $2,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $476 | $894,810680 claims |
| NovartisEntresto | $1,375 | $241,071163 claims |
| Johnson & JohnsonXarelto | $370 | $114,97491 claims |
| AstraZenecaFarxiga | $219 | $54,36946 claims |
| Boehringer IngelheimJardiance | $174 | $34,52231 claims |
| Novo NordiskOzempic | $16 | $12,28413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Albany
- Augustin DelagoAlbany$1.8M
- Edward PhilbinAlbany$226K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.